Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Wednesday following insider selling activity. $87.68 million flowed into the stock on the tick-up and $155.48 million flowed out of the stock on the tick-down, for a money net flow of $67.80 million out of the stock. Of all equities tracked, Gilead Sciences had the 6th highest net out-flow for the day. Gilead Sciences traded up $0.66 for the day and closed at $71.81Specifically, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the sale, the insider now directly owns 2,996,766 shares in the company, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. Insiders sold 666,819 shares of company stock valued at $52,303,086 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
GILD has been the topic of a number of research analyst reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $84.87.
The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market cap of $93,630.00, a price-to-earnings ratio of 7.60, a P/E/G ratio of -1.22 and a beta of 1.13.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
A number of large investors have recently made changes to their positions in GILD. Welch Investments LLC bought a new position in Gilead Sciences in the 3rd quarter valued at $108,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the last quarter. Penserra Capital Management LLC lifted its holdings in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences during the 1st quarter worth $143,000. Finally, Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $144,000. 74.62% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Investors Sell Shares of Gilead Sciences, Inc. (GILD) on Strength After Insider Selling” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/16/investors-sell-shares-of-gilead-sciences-inc-gild-on-strength-after-insider-selling.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.